This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050.

Given the success of the previous collection Diagnosis, Prevention and Treatment in Diabetic Nephropathy - Volume II, and the new advances in the field, we ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 205 ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

Autoimmune diseases make the immune system attack healthy tissues. These can affect organs like kidneys, leading to ...

Diabetes affects 80 million Indians and can lead to serious kidney issues like diabetic nephropathy. High blood sugar levels ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

The following is a summary of “Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...